REGENXBIO Inc. January 28, 2026 Please complete the form below to contact Kaplan Fox regarding the REGENXBIO Investigation: Join a Case First Name * Last Name * Email Address * Phone Number * Ticker Symbol Or Company Name * Please Insert Your Estimation Of Losses In USD * Are you a current or former employee of the company mentioned having traded above? * Yes No Captcha Submit If you are human, leave this field blank. Principle Contacts Jeffrey P. Campisi JCampisi@kaplanfox.comLaurence D. KingLKing@kaplanfox.com Kaplan Fox Alerts Investors of REGENXBIO Inc. (RGNX) to an Investigation of Possible Securities Law Violations Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against REGENXBIO Inc. (“REGENXBIO” or the “Company”) (NASDAQ: RGNX). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a REGENXBIO investor and have suffered losses, or if you have information that could assist in the REGENXBIO investigation, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing jcampisi@kaplanfox.com or by calling (212) 329-8571. On January 28, 2026, before the market opened, the Company disclosed that the FDA “placed a clinical hold on its investigational gene therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular CNS tumor) in a participant treated in its Phase I/II study.” The Company further disclosed that “[t]he FDA also placed a clinical hold on RGX-121, for the treatment of MPS II, also known as Hunter Syndrome, citing the similarities in products, study populations, and shared risk between the clinical studies . . . REGENXBIO has not yet received the full clinical hold letter and awaits additional details from the FDA.” Following this news, on January 28, 2026, the price of REGENXBIO stock declined from a closing price on January 27, 2026 of $13.41 per share, to trade as low as $9.92 per share, a decline of $3.49 per share, or by 26% during intraday trading. WHY CONTACT KAPLAN FOX Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. If you have any questions about this investigation, please contact: CONTACT:Jeffrey P. CampisiKAPLAN FOX & KILSHEIMER LLP800 Third Avenue, 38th FloorNew York, New York 10022(212) 329-8571jcampisi@kaplanfox.com Laurence D. KingKAPLAN FOX & KILSHEIMER LLP1999 Harrison Street, Suite 1501Oakland, California 94612(415) 772-4704lking@kaplanfox.com The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client. Any information you submit will be maintained as confidential. If Kaplan Fox, in its sole discretion, believes that you might be an appropriate client, Kaplan Fox will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases. Connect with Kaplan Fox. Receive a complimentary case review now. Contact Us Commvault Systems, Inc. See the Case REGENXBIO Inc. See the Case Navan, Inc. See the Case Nutanix, Inc. See the Case Lakeland Industries, Inc. See the Case BellRing Brands, Inc. See the Case Bath & Body Works, Inc. See the Case Gibraltar Industries, Inc. See the Case Wealthfront Corporation See the Case Chagee Holdings Limited See the Case AeroVironment, Inc. See the Case Aquestive Therapeutics, Inc. See the Case
